Imperagen appoints CEO following funding round

Manchester-based techbio company Imperagen has appointed Guy Levy-Yurista, PhD, as chief executive following the completion of a £5 million seed funding round.

Imperagen uses AI and quantum physics to engineer enzymes for industrial applications and is now entering its next phase of commercial and technological growth.

Guy brings extensive experience scaling AI, SaaS and life sciences businesses internationally. 

Most recently, he served as chief executive of Synthace, where he led a SaaS-focused commercial transformation that significantly increased recurring revenue and helped secure $45 million in funding, including a $35 million Series C round.

Earlier in his career, he held senior leadership roles at analytics unicorn Sisense and MicroStrategy, working across AI, enterprise technology and cloud infrastructure.

His appointment comes as Imperagen looks to build what it describes as a “Large Catalytic Model” for biocatalysis, with ambitions to transform how enzymes are engineered and deployed across the global chemicals industry.

The company say Guy’s experience scaling deep-tech businesses from technical innovation through to commercial growth and enterprise adoption will support its next stage of development, while its scientific founders remain central to the company’s long-term direction.

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.